Hero

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad announces closing of global offering

Celyad announces closing of global offering

Celyad announces pricing of $47.3 million global offering

Celyad announces pricing of $47.3 million global offering

Discover all news

Carousel

Social Feed

RT @Edison_Inv_Res: Update on @CelyadSA Clinical development with #CART CYAD-01 in #AML progressing. THINK interim data in Q418 https://t.c…

3 days ago

RT @Edison_Inv_Res: Update on @CelyadSA Clinical development with #CART CYAD-01 in #AML progressing. THINK interim data in Q418 https://t.c…

@Edison_Inv_Res Report on Celyad: Developing a sophisticated clinical strategy. https://t.co/q0PxYD9FYg

4 days ago

@Edison_Inv_Res Report on Celyad: Developing a sophisticated clinical strategy. https://t.co/q0PxYD9FYg

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and begins dosing first patient with seco… https://t.co/McuQCTJZFG

6 days ago

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and begins dosing first patient with seco… https://t.co/McuQCTJZFG

#ICYMI , Interview of @ChristianHomsy , CEO of Celyad at Refresh Meetup about the challenges CAR-T cell therapies f… https://t.co/6ibH5LsNEa

1 week ago

#ICYMI , Interview of @ChristianHomsy , CEO of Celyad at Refresh Meetup about the challenges CAR-T cell therapies f… https://t.co/6ibH5LsNEa

RT @Edison_Inv_Res: Update on @CelyadSA Clinical development with #CART CYAD-01 in #AML progressing. THINK interim data in Q418 https://t.c…

3 days ago

RT @Edison_Inv_Res: Update on @CelyadSA Clinical development with #CART CYAD-01 in #AML progressing. THINK interim data in Q418 https://t.c…

@Edison_Inv_Res Report on Celyad: Developing a sophisticated clinical strategy. https://t.co/q0PxYD9FYg

4 days ago

@Edison_Inv_Res Report on Celyad: Developing a sophisticated clinical strategy. https://t.co/q0PxYD9FYg

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and begins dosing first patient with seco… https://t.co/McuQCTJZFG

6 days ago

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and begins dosing first patient with seco… https://t.co/McuQCTJZFG

#ICYMI , Interview of @ChristianHomsy , CEO of Celyad at Refresh Meetup about the challenges CAR-T cell therapies f… https://t.co/6ibH5LsNEa

1 week ago

#ICYMI , Interview of @ChristianHomsy , CEO of Celyad at Refresh Meetup about the challenges CAR-T cell therapies f… https://t.co/6ibH5LsNEa